{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HCQ&page=2",
    "query": {
      "intervention": "HCQ",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HCQ&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T21:48:28.970Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04369742",
      "title": "Treating COVID-19 With Hydroxychloroquine (TEACH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine (HCQ)",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Calcium citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2020-04-15",
      "completion_date": "2021-04-01",
      "has_results": true,
      "last_update_posted_date": "2022-04-22",
      "last_synced_at": "2026-09-03T21:48:28.970Z",
      "location_count": 2,
      "location_summary": "Brooklyn, New York • New York, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04369742"
    },
    {
      "nct_id": "NCT00259610",
      "title": "Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 755,
      "start_date": "2004-05",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2014-07-17",
      "last_synced_at": "2026-09-03T21:48:28.970Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00259610"
    },
    {
      "nct_id": "NCT04435808",
      "title": "Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-04-14",
      "completion_date": "2020-07-15",
      "has_results": true,
      "last_update_posted_date": "2022-02-14",
      "last_synced_at": "2026-09-03T21:48:28.970Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04435808"
    },
    {
      "nct_id": "NCT04421664",
      "title": "Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Corona Virus Infection",
        "SARS-CoV Infection",
        "Coronavirus"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "McGill University Health Centre/Research Institute of the McGill University Health Centre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-03-25",
      "completion_date": "2020-08-17",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-09-03T21:48:28.970Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04421664"
    },
    {
      "nct_id": "NCT04382625",
      "title": "Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "SARS-CoV-2 Pneumonia",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kootenai Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-10",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-02-05",
      "last_synced_at": "2026-09-03T21:48:28.970Z",
      "location_count": 1,
      "location_summary": "Coeur d'Alene, Idaho",
      "locations": [
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04382625"
    },
    {
      "nct_id": "NCT04132505",
      "title": "Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma",
        "Stage IV Pancreatic Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2019-10-22",
      "completion_date": "2026-03-24",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-09-03T21:48:28.970Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04132505"
    },
    {
      "nct_id": "NCT01768572",
      "title": "To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "sarilumab SAR153191 (REGN88)",
          "type": "DRUG"
        },
        {
          "name": "tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "leflunomide",
          "type": "DRUG"
        },
        {
          "name": "subcutaneous placebo",
          "type": "DRUG"
        },
        {
          "name": "intravenous placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2013-03",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-09-03T21:48:28.970Z",
      "location_count": 14,
      "location_summary": "Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01768572"
    },
    {
      "nct_id": "NCT04354870",
      "title": "COVID-19 PrEP HCW HCQ Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine (HCQ)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2020-04-03",
      "completion_date": "2020-10-01",
      "has_results": true,
      "last_update_posted_date": "2022-12-14",
      "last_synced_at": "2026-09-03T21:48:28.970Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04354870"
    },
    {
      "nct_id": "NCT01326533",
      "title": "Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pre-diabetes"
      ],
      "interventions": [
        {
          "name": "hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 32,
      "start_date": "2011-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-02-26",
      "last_synced_at": "2026-09-03T21:48:28.970Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01326533"
    },
    {
      "nct_id": "NCT01897116",
      "title": "A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine (HCQ)",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib (VEM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2013-06",
      "completion_date": "2016-10-05",
      "has_results": false,
      "last_update_posted_date": "2020-05-29",
      "last_synced_at": "2026-09-03T21:48:28.970Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01897116"
    }
  ]
}